Martin Shkreli is good at niche pharma. eg PKAN is estimated to affect only about 5,000 people worldwide but he found a quicker route to approval as FDA isn't as hard with low TAM diseases so the moat might not be as big as we think but needs a niche generic expert :)
Martin Shkreli is good at niche pharma. eg PKAN is estimated to affect only about 5,000 people worldwide but he found a quicker route to approval as FDA isn't as hard with low TAM diseases so the moat might not be as big as we think but needs a niche generic expert :)